Navigation Links
Amylin Pharmaceuticals Reports 2007 Financial Results
Date:1/28/2008

Net product sales increased 48% over 2006 to $701 million

SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2007. The Company reported total revenue of $222.0 million for the quarter ended December 31, 2007, which includes net product sales of $194.7 million. Net loss was $76.9 million, or $0.57 per share for the quarter ended December 31, 2007. Net loss for the quarter ended December 31, 2007 includes a full year non-cash expense of approximately $17 million associated with the adoption of an employee stock ownership plan (ESOP). The Company reported total revenue of $781.0 million for the year ended December 31, 2007, which includes net product sales of $701.5 million. Net loss for the year ended December 31, 2007 was $211.1 million, or $1.59 per share. At December 31, 2007 the Company held cash, cash equivalents and short-term investments of approximately $1.1 billion.

"BYETTA and SYMLIN continued to experience growth in physician adoption and prescriptions, generating net product sales of over $700 million. In addition, we announced positive clinical data from our key development programs, including exenatide once weekly, BYETTA monotherapy, and our pramlintide-metreleptin obesity program," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. "For 2008, we remain confident in prospects for the continued growth of BYETTA and SYMLIN and we have aggressive development plans for the year. These plans balance investments across opportunities in the near, mid and long-term and include the completion of our Ohio manufacturing facility, a strong clinical program to expand a
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
2. Amylin Pharmaceuticals to Present at Research & Development Day
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
... modern medicine, could it be possible to treat th...ower //of meditation? According to a study, a wide... can significantly reduce the severity of congesti...is study indicate that transcendental meditation c...
...a having significantly higher serum levels of infl...th silent brain infarction//, have an elevated ris...hers. The results appear in the second issue for ...Respiratory and Critical Care Medicine, published ...
...researchers have received a $1.5 million grant fro... neurons// that play a major role in narcolepsy. ...rized by daytime sleepiness. The NIH grant will fu...her disorders linked to neurons that produce the p...
...alists at UT Southwestern Medical Center have foun... bacteria// that cause some of the most common acu...hers have looked for clues to an infection by trac...ng it. But that doesn’t always work because the ba...
Other Medicine News:Health News:Transcendental Meditation Can Help 2Health News:NCPAP Decreases Cerebrovascular Risk in OSA Patients 2Health News:NCPAP Decreases Cerebrovascular Risk in OSA Patients 3Health News:$1.5 Million Grant to Yale for Narcolepsy-Neurotransmitter Study 2Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3
(Date:8/26/2008).../ -- The Oregon Tourism Commission,launched its ne...ng Program,(Q Care) this week on http://www.Orego... created to support the tourism and,hospitality in...hasizing,the importance of quality customer servic...d resources to better serve Oregon,s visitors., "...
(Date:8/26/2008)...wswire/ -- Healthpoint today announced,that it has...iveness of a,widely prescribed enzymatic debriding...cars. The pilot study was prompted, in part, by cl...ophic scars and beneficial healing,properties asso... "Given the findings from the peer-reviewed litera...
(Date:8/25/2008)... Menstrual Blood May Offer Long-Lasting ...LDSMAR, Fla., Aug. 25 /- Time. It is ...hat there never seems to be enough,of it. And the ...hing just,for herself usually pales in comparison ...s led many women in need of quality time to seek o...
(Date:8/25/2008)...tment and Japanese Development Studies ... August 25 /- Genmab has,an...in chronic lymphocytic,leukemia and non-Hodgkin,s ...plans to begin four studies of,ofatumumab in chron...odgkin,s lymphoma (NHL) this year., "Genmab and G...
Breaking Medicine Technology:Oregon Tourism Commission Unveils New Online Customer Service Training Program 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Justice Department Reaches Settlement to Improve Conditions at a Nebraska Developmental Center 22972 1Justice Department Reaches Settlement to Improve Conditions at a Nebraska Developmental Center 22972 2Sparta Systems Selected by Genzyme to Optimize Quality Assurance Processes with TrackWise 6313 1Sparta Systems Selected by Genzyme to Optimize Quality Assurance Processes with TrackWise 6313 2Patient Receives vProtect 28TM 29 Luminal Shield in First Ever Vulnerable Plaque Clinical Trial 2557 1Patient Receives vProtect 28TM 29 Luminal Shield in First Ever Vulnerable Plaque Clinical Trial 2557 2Patient Receives vProtect 28TM 29 Luminal Shield in First Ever Vulnerable Plaque Clinical Trial 2557 3Research Links Low HDL Levels With Memory Loss 22970 1Research Links Low HDL Levels With Memory Loss 22970 2
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus
Rapid Immunoassay for the detection of Respiratory Syncytial Virus.
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients.
...en EZ RSV Test utilizes a new, improved format tha...id RSV detection. The testing device employs innov...ied reagents have already been applied to the test...ss, with clear-cut results shown by the appearance...
Medicine Products: